Nu-Med Plus (NUMD) Cash from Operations Growth (5y) (2017 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Nu-Med Plus | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.23% |
| Sep 30, 2025 | 35.34% |
| Dec 31, 2024 | 57.80% |
| Jun 30, 2024 | 54.64% |
| Mar 31, 2024 | 71.67% |
| Dec 31, 2023 | 50.45% |
| Sep 30, 2023 | 33.30% |
| Jun 30, 2023 | 25.35% |
| Mar 31, 2023 | 24.42% |
| Dec 31, 2022 | 29.39% |
| Sep 30, 2022 | 14.93% |
| Jun 30, 2022 | 50.98% |
| Mar 31, 2022 | 30.32% |
| Dec 31, 2021 | 13.33% |
| Sep 30, 2021 | -1.03% |
| Jun 30, 2021 | -5.93% |
| Mar 31, 2021 | -9.53% |
| Dec 31, 2020 | -8.44% |
| Sep 30, 2020 | -20.78% |
| Jun 30, 2020 | -22.78% |
| Mar 31, 2020 | -17.07% |
| Dec 31, 2019 | -27.70% |
| Sep 30, 2019 | -16.42% |
| Jun 30, 2019 | -23.25% |
| Mar 31, 2019 | -41.25% |
| Sep 30, 2018 | -30.18% |
| Jun 30, 2018 | -24.74% |
| Mar 31, 2018 | -17.75% |
| Dec 31, 2017 | -5.91% |
| Sep 30, 2017 | -36.72% |
| Jun 30, 2017 | -37.08% |
| Mar 31, 2017 | -20.14% |